RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc

Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

PopularRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
NAD+
Same goal
Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01
NAD+

Longevity

Vials · 500 / 1000 mg

01Protocol

Vials
500 / 1000 mg
Dosing data
Lab reference — not listed

02Quick calculator

Draw (100u)

—

Concentration

—

mg/mL

03Mechanism of action

NAD+ is a coenzyme central to energy metabolism and a substrate for sirtuins and PARP enzymes. Most human trials raise NAD+ indirectly with precursors such as nicotinamide riboside (NR); trials of injected NAD+ itself are scarce.

04Study endpoints

  • NADPARK (30 people with early Parkinson's, 30 days): oral NR raised brain NAD levels, changed cerebral metabolism, lowered inflammatory cytokines and was associated with mild clinical improvement.
  • Pilot RCT in 20 older adults with mild cognitive impairment (10 weeks): blood NAD+ rose 2.6-fold with NR; cognition scores stayed stable.

05Safety & regulatory findings

  • Precursors such as NR are sold as dietary supplements; injectable NAD+ is not an FDA-approved drug.
  • Both trials reported NR as well tolerated, with no between-group difference in adverse events in the cognitive-impairment trial. These findings are for NR, not injected NAD+.

06Citations

2 references · view